Unknown

Dataset Information

0

Cardiac noradrenergic deficiency revealed by 18F-dopamine positron emission tomography identifies preclinical central Lewy body diseases.


ABSTRACT:

Background

In Lewy body diseases (LBDs) Parkinson disease (PD), and dementia with Lewy bodies (DLB), by the time parkinsonism or cognitive dysfunction manifests clinically, substantial neurodegeneration has already occurred. Biomarkers are needed to identify central LBDs in a preclinical phase, when neurorescue strategies might forestall symptomatic disease. This phase may involve catecholamine deficiency in the autonomic nervous system. We analyzed data from the prospective, observational, long-term PDRisk study to assess the predictive value of low versus normal cardiac 18F-dopamine positron emission tomography (PET), an index of myocardial content of the sympathetic neurotransmitter norepinephrine, in at-risk individuals.

Methods

Participants self-reported risk factor information (genetics, olfactory dysfunction, dream enactment behavior, and orthostatic intolerance or hypotension) at a protocol-specific website. Thirty-four with 3 or more confirmed risk factors underwent serial cardiac 18F-dopamine PET at 1.5-year intervals for up to 7.5 years or until PD was diagnosed.

Results

Nine participants had low initial myocardial 18F-dopamine-derived radioactivity (<6,000 nCi-kg/cc-mCi) and 25 had normal radioactivity. At 7 years of follow-up, 8 of 9 with low initial radioactivity and 1 of 11 with normal radioactivity were diagnosed with a central LBD (LBD+) (P = 0.0009 by Fisher's exact test). Conversely, all 9 LBD+ participants had low 18F-dopamine-derived radioactivity before or at the time of diagnosis of a central LBD, whereas among 25 participants without a central LBD only 1 (4%) had persistently low radioactivity (P < 0.0001 by Fisher's exact test).

Conclusion

Cardiac 18F-dopamine PET highly efficiently distinguishes at-risk individuals who are diagnosed subsequently with a central LBD from those who are not.

Trial registration

Clinicaltrials

gov NCT00775853.

Funding

Division of Intramural Research, NIH, NINDS.

SUBMITTER: Goldstein DS 

PROVIDER: S-EPMC10760969 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cardiac noradrenergic deficiency revealed by 18F-dopamine positron emission tomography identifies preclinical central Lewy body diseases.

Goldstein David S DS   Holmes Courtney C   Sullivan Patti P   Lopez Grisel G   Gelsomino Janna J   Moore Sarah S   Isonaka Risa R   Wu Tianxia T   Sharabi Yehonatan Y  

The Journal of clinical investigation 20240102 1


<h4>Background</h4>In Lewy body diseases (LBDs) Parkinson disease (PD), and dementia with Lewy bodies (DLB), by the time parkinsonism or cognitive dysfunction manifests clinically, substantial neurodegeneration has already occurred. Biomarkers are needed to identify central LBDs in a preclinical phase, when neurorescue strategies might forestall symptomatic disease. This phase may involve catecholamine deficiency in the autonomic nervous system. We analyzed data from the prospective, observation  ...[more]

Similar Datasets

2011-11-01 | GSE21217 | GEO
2011-11-01 | E-GEOD-21217 | biostudies-arrayexpress
2020-03-18 | GSE131769 | GEO
2020-03-18 | GSE135565 | GEO
| S-EPMC2952433 | biostudies-literature
| S-EPMC3950258 | biostudies-literature
| S-EPMC8668184 | biostudies-literature
| S-EPMC9232920 | biostudies-literature
| S-EPMC7347147 | biostudies-literature
| S-EPMC7066555 | biostudies-literature